News Archive

Jun 2022

Jun 30, 2022 VIRALEZE™ relaunched by LloydsPharmacy in the UK (ASX Announcement)

Jun 07, 2022 Australian biotech back on the international stage

Jun 07, 2022 Starpharma one of a number of Australian companies in the US for major oncology conference

Jun 03, 2022 Shareholder Newsletter June 2022

May 2022

May 23, 2022 Starpharma's nasal spray effective against influenza A & B virus

May 18, 2022 SPL7013 in VIRALEZE™ virucidal against influenza A and B (ASX Announcement)

May 18, 2022 Starpharma’s (ASX:SPL) antiviral agent fights back against against influenza virus

Apr 2022

Apr 29, 2022 Quarterly Cashflow and Activities Report (ASX Announcement)

Apr 27, 2022 Starpharma to present DEP® at Boston ADC summit (ASX Announcement)

Apr 01, 2022 Starpharma (ASX:SPL) to relaunch VIRALEZE treatment in UK

Apr 01, 2022 Dr Jeff Davies appointed as non-executive director (ASX Announcement)

Apr 01, 2022 VIRALEZE™ to relaunch in the UK (ASX Announcement)

Mar 2022

Mar 04, 2022 Response to media article (ASX Announcement)

Mar 02, 2022 Active agent in Australian-developed nasal spray highly active against 'Omicron'

Mar 01, 2022 SPL7013 in VIRALEZE™ virucidal against Omicron (ASX Announcement)

Mar 01, 2022 Starpharma’s (ASX:SPL) nasal spray outperforms competitors against Omicron variant

Feb 2022

Feb 24, 2022 Dr Jeff Davies appointed as non-executive director (ASX Announcement)

Feb 21, 2022 Starpharma Interim Report and Half-Year Financial Results (ASX Announcement)

Feb 03, 2022 Starpharma (ASX:SPL) pens distribution deal in Saudi Arabia

Feb 03, 2022 VIRALEZE™ sales and distribution in Saudi Arabia and GCC (ASX Announcement)

Jan 2022

Jan 28, 2022 Starpharma’s (ASX:SPL) December quarter boosted by VIRALEZE success

Jan 28, 2022 Quarterly Cashflow and Activities Report (ASX Announcement)

Jan 27, 2022 Australian homegrown COVID-19 pipeline shows signs of maturity

Jan 20, 2022 Starpharma receives $7.7M R&D tax incentive refund (ASX Announcement)